Comparing microneedling with Botox to Meso-Botox for treating acne scars
Evaluation of the Efficacy and Safety of Microneedling Combined With Botulinum Toxin-A Versus Meso-Botox Injection in the Treatment of Atrophic Acne Scars: A Split-face Comparative Study
This study is testing whether combining microneedling with Botox works better than Meso-Botox injections for improving acne scars.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06544993 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness and safety of combining microneedling with Botulinum Toxin-A (BTX-A) against Meso-Botox injections in treating atrophic acne scars. The approach utilizes micro-Botox, which is a diluted form of BTX-A injected into the skin to target superficial muscle fibers and sebaceous glands, potentially improving the appearance of scars. The study aims to determine if this combination can enhance skin texture and reduce the psychological impact of acne scars. Participants will undergo a split-face comparison to assess the outcomes of each treatment method.
Who should consider this trial
Good fit: Ideal candidates are individuals with atrophic post-acne scars who meet the inclusion criteria.
Not a fit: Patients with active infections, skin cancer, or those who have had recent cosmetic procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the appearance of atrophic acne scars, enhancing patients' quality of life.
How similar studies have performed: While the combination of microneedling and BTX-A is a novel approach, similar studies have shown promising results with individual treatments for acne scars.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with atrophic post-acne scars. Exclusion Criteria: * Pregnancy and lactation. Ongoing infection within the targeted treatment region or active acne lesions. Skin cancer, or precancerous lesions. History of keloid formation. History of allergy to BTX. Patients with neuromuscular diseases, patients with pre-existing medical conditions that cause muscle weakness as myasthenia gravis. Patients who underwent Botox injection, during the last 6 months. Patients who were under treatment by systemic retinoids in the previous 6 months. Patients with a history of chemical peels or laser procedures within 6 months of the study period. Patients with bleeding disorders.
Where this trial is running
Sohag
- Sohag university Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Mariam N Latif, resident
- Email: mariam_nashaat_post@med.sohag.edu.eg
- Phone: 01228732523
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.